In specific embodiments of the invention, such systems may comprise renin expressing cell lines incubated in the presence or absence of one or more drugs, compounds, or other therapeutic agents; followed by the step of measuring the level of induced renin expression attributable to administration of the test PPAR-agonist compounds or combinations of such compounds, and selecting the test compound